Tuesday, 29 September 2015

Workshop on Awareness of Indian Pharmacopoeia and Indian Pharmacopoeia Reference Standards (IPRS)

NMIMS, Pharmacy, Mumbai is organizing Workshop on Awareness of Indian Pharmacopoeia and Indian Pharmacopoeia Reference Standards (IPRS). The details for the same are as follows:

Theme:     Workshop on Awareness of Indian Pharmacopoeia and Indian Pharmacopoeia Reference Standards (IPRS)
Dates:             7th October 2015.

Organized by:   SVKM's NMIMS. 

Location:           Mumbai.

New book published _API technology

A new book on "Active Pharmaceutical Ingredient (API) Technology" has been published recently. This book is as per 2015 Semester pattern (Semester V) of Savitribai Phule Pune University

The details for the same are as follows:

Author:                       Dr. Anwar Shaikh.

Publishers:                Knowledge Publications, Nashik

One-day course on scientific writing

Vivekananda College of Pharmacy and Ayurvidye Trust will jointly hold a one-day course on Smileys to Scientific Writing. The details for the same are as follows:

Theme:            Smileys to Scientific Writing

Dates:              November 27, 2015.

Location:          Vivekananda College of Pharmacy, Rajajinagar in Bengaluru.


Monday, 28 September 2015

National conference on nanotechnology in drug delivery research: Innovations, challenges & opportunities

NMIMS, Pharmacy, Mumbai is organizing "National conference on nanotechnology in drug delivery research: Innovations, challenges & opportunities". The details for the same are as follows:

Theme:     National conference on nanotechnology in drug delivery research: Innovations, challenges & opportunities.      
Dates:             16th-17th October 2015.

Organized by:   ICMR and SVKM's NMIMS. 

Location:           Mumbai.

Friday, 25 September 2015

Pharma academic research - Indian patent applications published on 25th Sept 2015

Every week of thousands of patent applications are published in India. The patent applications filed by the pharma academic research institutes in India go un-noticed.

We publish a list of Indian applications published related to pharma academics. This would provide us an idea about the kind of academic research being carried out in these institutes. For details of these patents, please write back to us at pharmaliterati@gmail.com

Application No
Anti-carcinogenic embryonic antigens activity of elaeocarpus
784/DEL/2014 A
1) Dr. Dinesh Kumar Garg
Not known
Monoclonal antibody specific for shigella flexneri and process for preparation thereof
820/DEL/2014 A
1) Urs, Radhika Madan
2) Mudili, Venkataramana
3) Ramlal, Shylaja
4) Tuteja, Urmil
5) Murali, Harishchandra Sripathy
6) Batra, Harsh Vardhan
A novel composition for herbal face wash and process for the preparation of the same
890/DEL/2013 A
1) Charu Gupta
2) Dhan Prakash
Amity University
A sustained release formulation coating methotrexate and folate nanoparticles and a method for preparing the same
804/DEL/2014 A
1) Sanat Mohanty
IIT, Delhi
Modified release compositions of triptans
129/MUM/2014 A
1) Manutosh Manoharrao Acharya
Not Known
New use of 2-substituted amino-5-thiazolyl analogues against diabetes, obesity and autoimmune diseases
1920/MUM/2013 A
1) Kamala Kunju Vasu
2) Pavitra Suresh Thacker
3) Jayesh Anilkumar Sharma
4) A. Abhiramasundari
B. V. Patel PERD Centre
Formulation of 'acnesome' a novel drug delivery system for acne
450/MUM/2014 A
1) Prof. (Dr.) Surendra Jain
Director, SIRT-Pharmacy, Sagar Campus, Ayodhya Bypass Road, Bhopal
Colloidal carrier system for CNS drugs
60/MUM/2014 A
1) Rahul Radheshyam Srivastav
2) Dr.(Mrs.) Ujwala A. Shinde
3) Amruta Vaidya
Not known
Novel imidazo 1,3,5-triazinylthiazoles
1919/MUM/2013 A
1) Kamala Kunju Vasu
2) Neelam Chauhan
3) Srikanth Gatadi
4) Dhaivatkumar Harikrishnabhai Pandya
5) Jayesh Anilkumar Sharma
B. V. Patel PERD Centre
Antileukemic activity of n-arylated amino derivatives against human cancer K-562 cell line.
367/MUM/2014 A
1) Dr. M. M. V. Ramana
2) Sharma Madhu Radheyshyam
Department Of Chemistry, University Of Mumbai.
A process for the synthesis of 1, 4-dihydropyridine derivatives and their antileukemic activity
625/MUM/2014 A
1) Dr. M. M. V. Ramana
2) Dr. R. S. Lokhande
3) Mehta Ankita Laxman
Department Of Chemistry, University Of Mumbai.
A process for the preparation of o-substituted benzophenone derivatives
443/MUM/2014 A
1) Dr. M. M. V. Ramana
2) Betkar Rahul Ramesh
3) Nimkar Amey Pramod
4) Ranade Prasanna Bhalchandra
Department Of Chemistry, University Of Mumbai.
A herbal formulation
806/MUM/2014 A
1) Savita Dixit
Department Of Chemistry, MANIT, Bhopal
A novel dissolution medium and a process for analyzing the effect of alcohol on drug release and permeation pattern
664/MUM/2014 A
1) Anagha M. Joshi
2) Atmaram P. Pawar
3) Shivajirao S. Kadam
Not Known
Oral films
3658/MUM/2013 A
1) Yadav Akanksha Bindeshwari Prasad
2) Pawar Harshal Ashok
3) Chivate Amit Ashok
Not known
Determination of Withaferin a in rat plasma by high performance thin layer chromatography(HPTLC) method.
687/MUM/2014 A
1) Nancy Pandita
2) Sweta Jha
Nancy Pandita School Of Science, SVKM'S NMIMS Deemed-to-be University
A novel gastro-retentive delivery of fluroquinolone antibacterial agents
4102/MUM/2013 A
1) Waghulde, Sandeep Onkar
2) Juvatkar, Pritam Vijay
3) Gorde, Nilesh Keshavrao
4) Naik, Pravin Pandurang
5) Jain, Vishal Ramesh
6) Sikdar, mrinal R.
7) Laxmikant Arun Desale
8) Sarangi, Manoj kumar
Not Known
Natural wound healer comprising herbal drug compositions for wound healing as topical applications and internal uses
913/MUM/2014 A
1) Yogesh P. Talekar
Not Known
Topical formulation comprising morinda tinctoria and allium sativum for wound healing
2927/CHE/2013 A
1) Balaguru, R. John Bosco
2) Brindha, P.
3) Senthilkumar, S.
Sastra University

Tuesday, 22 September 2015

Dengue news: Vaccines update from Serum insitute

Times of India reports that Asia's largest vaccine maker, Pune-based Serum Institute will develop a biologic drug to treat all four strains of the dengue virus, and is in the process of applying to the Ministry of Science and Technology for a "fast-track approval" to roll-out the treatment in the country. Serum, which has tied up with US-based biotechnology company Visterra to use its technology to develop the monoclonal antibody, hopes to commercialize the treatment within 12-18 months of getting the regulatory approvals, Serum Institute CEO Adar Poonawalla told TOI.

The biologic treatment (monoclonal anti-body) once rolled out will be given as an injection to cure dengue, and cost between Rs 5,000-10,000 for a single dose. Only one dose will be required. While Serum's biologic drug could become one of the first treatments to roll out, other biggies like Sanofi and Novartis are also in the race to launch a vaccine may happen over the next few years.

If the trials are successful, Serum could perhaps become the first company to offer a cure for the dreaded infection which has shown the worst outbreak, with several deaths, and cases doubling this year.

Under the terms of the agreement, Serum Institute has an exclusive license to commercialize the treatment for the Indian subcontinent, including India, Pakistan, Bangladesh, Nepal, Bhutan, Maldives, and Sri Lanka. It has paid Visterra a $5 million upfront payment, and up to $34 million based on the achievement of certain development and commercial milestones.

Serum Institute will fund and be responsible for the clinical development of VIS513 in the licensed territories, including the filing of regulatory applications. The companies will establish a joint steering committee to coordinate the development for the Indian subcontinent.

The Pune-based company is also working on a dengue vaccine, like the other global biggies to be given as a preventive. The development of a vaccine will take three to four years, as it has to be tested on a wide-range and number of subjects, he added.

Source: http://timesofindia.indiatimes.com/business/india-business/Pune-firm-set-to-roll-out-cure-for-dengue/articleshow/49052684.cms

Dengue breakthrough: Bengaluru-based lab develops botanical pill

At present, there is no specific approved vaccine or therapy to prevent dengue fever. But now a Bengaluru-based lab has come up with a tablet to treat the dreaded vector-borne disease.

Bengaluru-based Micro Labs Ltd has recently launched a botanical pill 'Caripill' that helps to increase the platelet count in dengue patients.

The drug, which has been approved by the scientific and regulatory authority, is made from Carica Papaya leaf extract and reportedly does not have any side-effects. The pill has been proven to be safe and effective in about one lakh patients across the country.

The lab claims that the drug, which underwent clinical trials on 250 patients, has shown positive results with a dramatic decrease in the haemorrhage condition. Besides, none of the patients had to undergo blood transfusion so far.

It is believed that Caripill is the first drug to be backed by adequate scientific data to increase the platelet count in dengue cases.

Since the pill has shown its immense potential in treating dengue, the lab is confident that it can be administered on patients with other life-threatening diseases, like leukaemia among others, which requires intense chemotherapy leading to loss of platelets.

Caripill, which has been made available in all major pharmacies across India, costs Rs 25 per tablet with the dosage of administering one pill (1100 mg) three times a day, for five days.

The national capital of Delhi is grappling with its worst dengue outbreak in five years with the disease claiming 12 lives in the city this year so far. As of September 12, a total of 1,872 patients have tested positive for the vector borne disease in Delhi.

According to World Health Organisation (WHO), dengue is emerging as a serious public health problem globally, with 2.5 billion people at risk and 50 million dengue infections occurring annually.

Source: http://zeenews.india.com/news/health/health-news/dengue-breakthrough-bengaluru-based-lab-develops-botanical-pill-to-increase-platelet-count_1797796.html

Monday, 21 September 2015

Pharma firm hikes life-saving drug price by 5,500%

The medical community in USA is outraged by a 5,500 percent price hike for Daraprim®, after a big New York based pharmaceutical company purchased the patent for it. The drug has been on the market for over 60 years, and can be essential to certain AIDS and cancer treatments.

The New York-based Turing Pharmaceuticals raised the price of Daraprim®, from $13.50 to $750 per pill in just over a month after buying the rights for the drug from Impax Laboratories.

The drug is used to treat toxoplasmosis, the second most common food-borne disease that affects patients suffering from AIDS and cancer. It has been produced since 1953 and is on the WHO List of Essential Medicines. But now medical associations are beating their drums about the sudden price hike and potential affordability of Daraprim®, as a treatment.

Please see:
·  http://www.rt.com/usa/316046-pharma-daraprim-price-hike/
·  http://motherboard.vice.com/read/when-drug-startups-make-big-pharma-look-like-the-good-guy

Saturday, 19 September 2015

Sun Pharma sells divisions of Ranbaxy to Strides Arcolab

The Economic Times reports that Sun Pharmaceutical Industries Ltd is selling erstwhile Ranbaxy's two divisions in central nervous system (CNS) segment in India to Strides Arcolab for Rs 165 crore. Sun Pharma and Strides have entered into a definitive agreement related to erstwhile Ranbaxy's 'Solus' and 'Solus Care' divisions operating in the central nervous system (CNS) segment in India, the company said in a statement.  The agreement involves transfer of these two marketing divisions, along with employees to Strides for a consideration of Rs 165 crore, it added.

Commenting on the development, Sun Pharma CEO-India Business Abhay Gandhi said, "We have evaluated each and every therapy segment that we are present in and how these businesses can grow going forward. Based on this evaluation, we firmly believe that the potential of Solus and Solus Care divisions can be greatly enhanced with the focus that Strides will put in growing them. The divestment will help these divisions, its customers and the team".

Strides India President (Brands) Subroto Banerjee said, the acquisition of Solus and Solus Care divisions is of strategic significance to the growth of the company's branded business in India. "The rich product portfolio and capable teams of these two divisions will help us establish a strong footing in the fast growing
CNS market of India," he said, adding the product portfolio of Strides and these divisions will strategically complement each other very well. "The speciality nature of CNS products makes brand equity and customer relationships, key determinants of success. The Solus and Solus Care divisions readily qualify for both these parameters," Banerjee said.

Read more at:

National Elocution Competition - 2015 by IPA

The Education division of Indian Pharmaceutical Association (IPA) has announced the National Elocution Competition for the year 2015. 

Please see the details: http://www.ipapharma.org/news/NEC%202015.pdf

The competition is divided into four rounds:
Duration and timing
Duration and timing will be fixed by the head of the institution
Duration and timing will be fixed by the State Coordinator
Duration and timing will be fixed by the Convener, NEC-2015
Duration and timing will be fixed by the Convener, NEC-2015
3 judges amongst teaching staff to be appointed by
Head of Institution where competition is to be conducted.
3 judges to be appointed by the State Coordinator of respective state where competition is to be conducted.
5 judges to be appointed by the Convener, NEC-2015.
5 judges to be appointed by the Convener, NEC-2015.
Head of Institution will select topic for competition and the same should be given to participants at least three days prior to the competition.
“Responsible use of Antibiotics Saves Lives".
Will be informed in due course.
Will be intimated to the Winners of the Semi Final round.
Time Schedule
Before 15th October 2015
Before 15th November 2015.
Before 30th November 2015.
During 67th IPC at, Mysore in December 2015.